Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

Blood

Volumn 98, Issue 13, 2001, Pages 3575-3583

  Estey, Elihu H ^a,b   Thall, Peter F ^a   Cortes, Jorge E ^a   Giles, Francis J ^a   O'Brien, Susan ^a   Pierce, Sherry A ^a   Wang, Xuemei ^a   Kantarjian, Hagop M ^a   Beran, Miloslav ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; ITRACONAZOLE; LISOFYLLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETINOIC ACID; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLAST TRANSFORMATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; HUMAN; INFECTION; INFECTION PREVENTION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; PRELEUKEMIA; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; STATISTICAL MODEL;

EID: 0035895052     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.13.3575     Document Type: Article

References (23)

1. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (RAEB, RAEB-t, or AML) on outcome of AML-type chemotherapy. Blood. 1997;90:2969-2977.
2. Beran M, Estey E, O'Brien S, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol. 1999;17:2819-2830.
3. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of arabinosyl cytosine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11:116-124.
4. Estey E, Plunkett W, Gandhi V, Rios M, Kantarjian H, Keating M. Fludarabine and arabinosylcytosine therapy for refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993;9:343-350.
5. Estey E, Thall PF, Wang X. Routine use of fludarabine- or topotecan-containing chemotherapy is not indicated in AML, RAEB-t, or RAEB (abstract). Blood. 2000;96(11):504a.
6. Estey E, Kantarjian H, Keating M. Idarubicin plus continuous-infusion high-dose cytosine arabinoside as treatment for patients with acute myeloid leukemia or myelodysplastic syndrome. Semin Oncol. 1993;20(suppl 8):1-5.
7. Estey EH, Thall PF, Reed P, et al. Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy. Leukemia. 1999;13:850-854.
8. Estey EH, Thall PF, Pierce S, et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid and/or granulocyte-colony stimulating factor in poor prognosis newly-diagnosed non-APLAML and MDS. Blood. 1999:93:2478-2484.
9. Greenberg P, Cox C, LeBeau M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;2079-2088.
10. List A, Maziarz R, Stiff P, et al. Lisofylline reduces infection rate and improves survival in patients undergoing allogeneic bone marrow transplantation: results of a randomized placebo-controlled trial (abstract). Blood. 1996;88(suppl 1):459a.
11. Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;53:457-814.
12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;60:163-170.
13. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
14. Therneau TM, Grambsch PM. Modeling Survival Data. New York, NY: Springer; 2000.
15. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526.
16. Venables WN, Ripley BD. Modern Applied Statistics With Splus, 3rd ed. New York, NY: Springer; 1999.
17. Cleveland WS. Robust locally-weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979;74:829-836.
18. Becker RA, Chambers JM, Wilks AR. The New S Language. Pacific Grove, CA: Wadsworth; 1988.
19. Therneau TM. A package for survival analysis in S. Rochester, MN: Mayo Clinic Foundation; 1994.
20. Estey E, Thall P, Andreeff M, et al. Use of G-CSF before, during, and after fludarabine + ara-C induction therapy of newly-diagnosed AML or MDS: comparison with fludarabine + ara-C without G-CSF. J Clin Oncol. 1994;12:671-678.
21. Cortes J, Estey E, O'Brien S, et al. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer. 2001;92:7-14.
22. Radomski KM, Gandhi V, Srivastava D, et al. Interim analysis of cytarabine and cladribine combination therapy in acute myeloid leukemia (abstract). Blood. 2000;96(11):327a.
23. Rosenberger WF, Lachin JM. The use of response-adaptive designs in clinical trials. Control Clin Trials. 1993;14:471-484.